Search for: "BRISTOL-MYERS SQUIBB"
Results 701 - 720
of 863
Sorted by Relevance
|
Sort by Date
27 Oct 2018, 10:58 am
Bristol-Myers Squibb, Co. [read post]
4 Jan 2019, 9:16 pm
On December 5, 2018, the General Court ruled in favor of the European Commission in an action brought by Bristol-Myers Squibb Pharma (BMS) against the Commission and the European Medicines Agency (EMA) in the case, T‑329/16, read here. [read post]
4 May 2016, 9:26 am
Bristol-Myers Squibb Co., CV. [read post]
25 Nov 2012, 1:00 pm
Under Bristol-Myers Squibb v Paranova condition ("the BMS conditions"), Condition 5 requires the importer to give notice to the trade mark owner before any repackaged product is put on sale, and, on demand, supplies him with a specimen. [read post]
11 Dec 2013, 4:30 am
Bristol-Myers Squibb Co., 2013 U.S. [read post]
6 May 2013, 4:33 pm
Thus, reciting Bristol-Myers Squibb Co. v Ben Venue Labs. [read post]
11 Mar 2019, 10:15 am
Bristol-Myers Squibb Co., 919 F.3d 699 (2d Cir. 2019) followed suit and unanimously affirmed snap removal as a procedural vehicle to remove to federal court. [read post]
28 Mar 2008, 7:25 am
Proponents have withdrawn resolutions at Abbott Laboratories, Aetna, Bristol-Myers Squibb, Eli Lilly, General Electric, IBM, Johnson & Johnson, McDonald's, Medco, WellPoint, ExxonMobil, Merck, Target, and Waste Management after many of the companies agreed to post statements on health care reform on their Web sites. [read post]
2 Dec 2011, 2:00 pm
Bristol-Myers Squibb Co., 2011 WL 4708850, at *3 (D. [read post]
3 Mar 2012, 5:36 pm
Bristol-Myers Squibb, 97 F. [read post]
5 Jul 2007, 10:37 am
Squibb & Sons, Inc. v. [read post]
18 Jan 2009, 4:48 pm
Dasatinib is an anti-cancer drug belonging to the class of tyrosine kinase inhibitors first approved in the United States on June 28, 2006 and marketed by Bristol-Myer Squibb (BMS) under the brand name Sprycel. [read post]
21 Jun 2017, 4:26 am
” Briefly: At The George Washington Law Review’s On the Docket blog, Alan Morrison looks at Monday’s decision in Bristol-Myers Squibb Co. v. [read post]
17 Nov 2010, 1:48 am
(FDA Law Blog) Crestor (Rosuvastatin) – US: AstraZeneca defeats Teva’s claim that Crestor infringes Teva’s patent (Orange Book Blog) Crestor (Rosuvastatin) – US: AstraZeneca files patent infringement suit against Watson in response to Para IV certification (Patent Docs) Efexor (Venlafaxine) – Australia: Federal Court blocks generic Efexor-XR: Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth Australia Pty Ltd (Patentology) (BAZPAT) (GenericsWeb) Fipronil – UK:… [read post]
20 Nov 2011, 10:31 pm
The court’s distinction is not a commercial one—and I would have thought that it would by now have been safely relegated to the dustbin of obsolete and antiquated notions; see Bristol-Myers Squibb Co. v. [read post]
18 Jan 2017, 10:19 am
(relisted after the January 6 and January 13 conferences) Bristol-Myers Squibb Co. v. [read post]
18 Jun 2012, 1:38 pm
., and similar pending cases against Johnson & Johnson, Merck Co. and Bristol-Myers Squibb. [read post]
31 Jul 2023, 1:47 pm
” Bristol–Myers Squibb Co. v. [read post]
26 Jun 2015, 8:05 am
Bristol-Myers Squibb, CN 91-21770, Tx Dist. [read post]
3 Mar 2010, 5:05 am
‘The solution lies in resources’ says FDA Commissioner Hamburg (FDA Law Blog) Products Actoplus MET (Pioglitazone) – US: Takeda files patent infringement suit against Aurobindo following Para IV certification as part of ANDA to manufacture generic Actoplus MET (Patent Docs) Advair diskus (Fluticasone, Salmeterol) – US: PTO denies PTE for Advair diskus patent; Office again clarifies that PTEs are not availabile for ‘synergistic combinations’ containing… [read post]
